One of Cuba’s coronavirus vaccines has shown 62 per cent efficacy in late-stage trials, using just two out of the three recommended doses.
Phase 3 interim results presented over the weekend for the Soberana 2 vaccine, named after the Spanish word for sovereign, surpassed efficacy thresholds required for approval by regulators and health agencies worldwide, including the World Health Organization.
Vicente Vérez Bencomo, director-general at the country’s Finlay Institute of Vaccines, said it was a very encouraging result?“obtained in a scenario of viral variant circulation”.
您已閱讀19%（577字），剩余81%（2494字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。